[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.129.96. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News and Perspectives
August 22/29, 2007

Postmarket “Pharmacovigilance” Program on Alert for Adverse Events From Drugs

JAMA. 2007;298(8):851-852. doi:10.1001/jama.298.8.851

As reports of adverse events from commonly used drugs continue to come to public attention, critics have stepped up demands for new and improved postmarket surveillance efforts.

While the US Food and Drug Administration (FDA) is rethinking its policies, independent “pharmacovigilance” endeavors are performing their own analyses and sounding alarms about potential dangers of numerous prescription drugs. Investigators in one program, called Research on Adverse Drug Events and Reports (RADAR), hope to improve patient safety through earlier detection of serious adverse drug reactions.

First Page Preview View Large
First page PDF preview
First page PDF preview
×